GlassScriptPhysician profile
Gerri Hempfling
NPI 1154694818
$5,158.83
in general payments reported to CMS, 2019-2025
30 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,433 · 2022: $1,015 · 2023: $673 · 2024: $671 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,708.20 | 2021 | |
| Amgen INC. | $790.28 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $389.50 | 2021-2025 | Lifevest |
| Abiomed | $284.60 | 2022-2025 | Impella |
| Abbott Laboratories | $198.88 | 2022-2025 | 2nd Gen Centrimag Primary Console, Cardiomems, Mitraclip |
| Astellas Pharma US INC | $196.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $181.95 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $130.99 | 2022-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.49 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $127.81 | 2021-2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $125.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $114.53 | 2021-2023 | |
| Pfizer INC. | $94.75 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $91.32 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $89.59 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $82.20 | 2023-2024 | Barostim Neo System |
| Medtronic, INC. | $76.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $71.26 | 2021-2023 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $40.78 | 2021-2022 | |
| Terumo Medical Corporation | $39.76 | 2024-2025 | Metacross Otw, Glidewire, Navicross |
| Livanova USA, INC. | $36.47 | 2021-2023 | Lifesparc |
| Kowa Pharmaceuticals America, INC. | $34.59 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.78 | 2021 | |
| Atricure, INC. | $18.13 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.14 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.27 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $15.20 | 2022 | |
| Baxter Healthcare | $14.87 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $12.68 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerri Hempfling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.